Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register
Authors' conclusion
Inflammatory biomarkers and absence of DMARD treatment were associated with increased risk of mortality in patients with RA-ILD.
Study context
- Population
- Patients with RA and prevalent ILD from the German biologics register RABBITRA-ILD cases of 15,566
- Participants
- 381 patients
- Exposure
- DMARD treatment (non-TNFi bDMARDs, JAKi, no DMARD) vs tumour necrosis factor inhibitors (TNFi) or any DMARD; inflammatory biomarkers and mortality
- Outcome
- All-cause mortality
Methodological detailsregister-based (RABBIT), time-varying Cox regression
- Register-based (RABBIT)
- Time-varying Cox regression
Main finding
As reported in the abstract
Adjusted hazard ratio (95% CI)
Non-TNFi bDMARDs + JAKivs TNFijoint aHR; time-varying Cox regression (main approach)
0.56(0.33–0.97)
No DMARDvs Any DMARD
2.03(1.23–3.35)
Observational data: associations, not effects.
Original publication
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register. RMD Open. Published 4 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →